Does anybody know how many shares are short and the days to cover?
Anybody know where one could find that information?
In Nasdaq, for May 15, it shows 16M shorts. There's probably much more than that with the ASCO run up in pps.
Stock was manipulated the whole day to drive it up to allow those in the know (again) to dump at a high price, before the SEC filing that they knew would most likely drive selling because people might speculate that the VP messed up the science, and don't realize right away that it was due to the insider trading allegations. My opinion anyway. Maybe there is another deal in the works that insiders have leaked to their close associates. And maybe they will also be going to prison soon.
I actually thought at first that the VP was fired because of his insistence on pursuing the HIV trials which I am inclined to believe won't go anywhere but simply waste resources.
ONTY-380 (ARRY-380) and Ipatasertib had clinical updates last ASCO but mgmt didn't mention them as additional value drivers in the Jefferies talk when they can also bring in tons of revenue when successful. ONTY380 had well publicized results and drove ONTY pps up more than 25%. There were two Genentech posters on Ipatasertib but I can't find details on the presentations. Mgmt should also mention those developments during corporate presentations. It makes their chemistry, research, and scientific team look much better when they have more successful molecules to talk about.
In the MARRIANE update which tanked the pps, Kadcyla as single agent is at least as good as Herceptin + taxane. Gastric results are coming.
Now 853 single agent is also highly active in RR ovarian cancer. Add paclitaxel or cisplatin to early stage and results maybe more impressive.
Again, Avastin in OC ph3 AURELIA study got up to 53% ORR for Avastin + paclitaxel, with 30% for paclitaxel alone, if I interpreted the table correctly. However, Avastin plus topotecan or doxorubicin only achieved 17-18% ORR.
It is still possible that patients in 853 study are in less advance disease than in AURELIA.
For one recent RS and the effect on price action, check out LXRX. Showed volatility, but largely up now. If ZGNX behaves the same way, there's an opportunity to make money on short term trades. The behavior usually depends on demand by institutions, which reflects on confidence in investing in the company. I've seen RS that was followed by decline in pps by as much as 20%.
Bought back some at 13.86 but already sold them at 14.55. I also had buy orders for 13.50 and 13.20 that didn't get hit. PPS could still go sub 14 after options expiration plus Grexit.
As of now though, that OC single agent result is really impressive. Kadcyla gastric cancer results will send pps soaring to 20.
It looks like a good buying opportunity tomorrow.
I haven't bought because of my lingering concerns about activation of proto-oncogenes or inactivation of tumor suppressor genes due to random integration of lentiglobin. The RAC position adds to my concern. Is the risk of cancer/reward ratio that much favorable compared to lifetime ERT use in B-thal major?
Should patients bank some of their HSCs before initiation of treatment, just to be safe?
Faosto, can you give me a good paper on these self-inactivating constructs? I read one paper on lentiglobin from the BB site, and it still talks about random integrations, although there was evidence on less preference for promoters/oncogenes.
At the end of the day, or FDA reckoning day, it will come down to risk/benefit. Maybe the risk will be considered by the FDA to be extremely low and the benefits to be huge. What will be considered tolerable risk? One good thing is that there are good drugs for liquid cancers now.
Yes, I wish I bought at $40, but my skeptic science stopped me. Without a definite FDA nod to the technology, as an investor, the price now presents too high a risk/reward ratio. Hope I'm mistaken.
Screen for integration events in the HSCs before transplant will definitely reduce the risk. Is that part of the protocol? A single cell PCR perhaps, but it will be time consuming and labor intensive to grow separate transduced cells. The risks of microbial contamination also increases. It does not seem to be practical. Perhaps a PCR of the pooled transductants right before infusion, using primers specific for the lenti and known oncogenes will at least provide an answer. Even that may be tough to validate.
Anyway, today I decided to play it safe and buy AMGN instead. BLUE will have to wait.
Very slow retreat, Goducks. You might not see $10 until 2 or 20 yrs from today. It maybe better for you to follow some other stock.
IMGN has ~270M by month's end which is enough to fund operation into 2017. Add partner payments to that. But I wouldn't mind if shares are offered if pps touches $17-18. In the meantime, the partnered ADCs will mature and bring in more milestone revenues, at the same time continue to validate the ADC technology.
853 result is from phase 1, but the patients are non-responsive to standard platinum/taxane treatment. Some partial responders may later convert to complete response. Since the patients are refractory to standard treatments, ph2 results may be enough for an NDA filing.
BT-062, which IMGN can opt in, gave good ph2 results. That would be the product that would be most advance, and for which IMGN will have a large share of revenue.
I'm impressed! The future looks bright. Company seems to have brilliant scientists and mgmt seems to know what to do with the science. Profitability in 2018 and no need to sell new shares. Revenues will probably equal burn rate by early 2016. Clearly a buyout prospect.
The only question is at what pps should I go all in before more good news drives the pps up higher?
Do you think deletion from Russell index contributed to the Grexit debacle? ARRY had a huge drop vs my other btechs.
I'm doing due diligence on AERI to decide on whether to ride this back to 35 or short it if pps goes up more, and saw a paper on the use of once a day travoprost and timolol. AERI ph3 just looked at superiority over timolol. What is your take on the travo/timolol use vs Rhopressa latanoprost? What is supposed to be the advertised advantage of Rhopressa over the travo/timolol combo?
Except that there are already 2 approved antibodies to CD20, in addition to rituximab, that MDs have been combining with Imbruvica for CLL. I'm not sure how much market share 1101 can get once approved. However, TGTX also has a differentiated PI3k inhibitor in 1202, in addition to the other newer drugs.
I am not sure whether this is a good buy at $17, or somewhat over priced given that approval for those 2 drugs may be 2 yrs away or more, and both have competitors in the same class of drugs..